309 related articles for article (PubMed ID: 2259314)
1. Developments in 5-hydroxytryptamine receptor pharmacology in migraine.
Peroutka SJ
Neurol Clin; 1990 Nov; 8(4):829-39. PubMed ID: 2259314
[TBL] [Abstract][Full Text] [Related]
2. The pharmacology of current anti-migraine drugs.
Peroutka SJ
Headache; 1990 Jan; 30(1 Suppl):5-11; discussion 24-8. PubMed ID: 1969855
[TBL] [Abstract][Full Text] [Related]
3. Present and future of 5-HT receptor agonists as antimigraine drugs.
Pauwels PJ; John GW
Clin Neuropharmacol; 1999; 22(3):123-36. PubMed ID: 10367177
[TBL] [Abstract][Full Text] [Related]
4. 5-Hydroxytryptamine receptor subtypes and the pharmacology of migraine.
Peroutka SJ
Neurology; 1993 Jun; 43(6 Suppl 3):S34-8. PubMed ID: 8389009
[TBL] [Abstract][Full Text] [Related]
5. [Central serotonin receptors. Principal fundamental and functional aspects. Therapeutic applications].
Moulignier A
Rev Neurol (Paris); 1994; 150(1):3-15. PubMed ID: 7801037
[TBL] [Abstract][Full Text] [Related]
6. An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy.
Villalón CM; Centurión D; Valdivia LF; De Vries P; Saxena PR
Proc West Pharmacol Soc; 2002; 45():199-210. PubMed ID: 12434581
[TBL] [Abstract][Full Text] [Related]
7. Is there a relationship between serotonin receptor subtypes and selectivity of response in specific psychiatric illnesses?
Montgomery SA; Fineberg N
Br J Psychiatry Suppl; 1989 Dec; (8):63-9. PubMed ID: 2692641
[TBL] [Abstract][Full Text] [Related]
8. Expression of mRNA for the serotonin 5-hydroxytryptamine1D beta receptor subtype in human and bovine cerebral arteries.
Hamel E; Fan E; Linville D; Ting V; Villemure JG; Chia LS
Mol Pharmacol; 1993 Aug; 44(2):242-6. PubMed ID: 8394988
[TBL] [Abstract][Full Text] [Related]
9. Antimigraine drug interactions with serotonin receptor subtypes in human brain.
Peroutka SJ
Ann Neurol; 1988 May; 23(5):500-4. PubMed ID: 2898916
[TBL] [Abstract][Full Text] [Related]
10. Differential expression of sumatriptan-sensitive 5-hydroxytryptamine receptors in human trigeminal ganglia and cerebral blood vessels.
Bouchelet I; Cohen Z; Case B; Séguéla P; Hamel E
Mol Pharmacol; 1996 Aug; 50(2):219-23. PubMed ID: 8700126
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and serotonergic activity of 3-[2-(pyrrolidin-1-yl)ethyl]indoles: potent agonists for the h5-HT1D receptor with high selectivity over the h5-HT1B receptor.
Sternfeld F; Guiblin AR; Jelley RA; Matassa VG; Reeve AJ; Hunt PA; Beer MS; Heald A; Stanton JA; Sohal B; Watt AP; Street LJ
J Med Chem; 1999 Feb; 42(4):677-90. PubMed ID: 10052975
[TBL] [Abstract][Full Text] [Related]
12. Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytryptamine and [3H]alniditan.
Leysen JE; Gommeren W; Heylen L; Luyten WH; Van de Weyer I; Vanhoenacker P; Haegeman G; Schotte A; Van Gompel P; Wouters R; Lesage AS
Mol Pharmacol; 1996 Dec; 50(6):1567-80. PubMed ID: 8967979
[TBL] [Abstract][Full Text] [Related]
13. 3-(Piperazinylpropyl)indoles: selective, orally bioavailable h5-HT1D receptor agonists as potential antimigraine agents.
Chambers MS; Street LJ; Goodacre S; Hobbs SC; Hunt P; Jelley RA; Matassa VG; Reeve AJ; Sternfeld F; Beer MS; Stanton JA; Rathbone D; Watt AP; MacLeod AM
J Med Chem; 1999 Feb; 42(4):691-705. PubMed ID: 10052976
[TBL] [Abstract][Full Text] [Related]
14. 5-HT in nervous system disease and migraine.
Fozard JR; Kalkman HO
Curr Opin Neurol Neurosurg; 1992 Aug; 5(4):496-502. PubMed ID: 1515690
[TBL] [Abstract][Full Text] [Related]
15. [Role of serotonin and other neuroactive molecules in the physiopathogenesis of migraine. Current hypotheses].
Hamon M; Bourgoin S
Pathol Biol (Paris); 2000 Sep; 48(7):619-29. PubMed ID: 11072640
[TBL] [Abstract][Full Text] [Related]
16. F 11356, a novel 5-hydroxytryptamine (5-HT) derivative with potent, selective, and unique high intrinsic activity at 5-HT1B/1D receptors in models relevant to migraine.
John GW; Pauwels PJ; Perez M; Halazy S; Le Grand B; Verscheure Y; Valentin JP; Palmier C; Wurch T; Chopin P; Marien M; Kleven MS; Koek W; Assie MB; Carilla-Durand E; Tarayre JP; Colpaert FC
J Pharmacol Exp Ther; 1999 Jul; 290(1):83-95. PubMed ID: 10381763
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological properties of the receptor(s) involved in the 5-hydroxytryptamine-induced contraction of the feline middle cerebral artery.
Hamel E; Robert JP; Young AR; MacKenzie ET
J Pharmacol Exp Ther; 1989 Jun; 249(3):879-89. PubMed ID: 2732950
[TBL] [Abstract][Full Text] [Related]
18. The relevance of preclinical research models for the development of antimigraine drugs: focus on 5-HT(1B/1D) and CGRP receptors.
Gupta S; Villalón CM
Pharmacol Ther; 2010 Oct; 128(1):170-90. PubMed ID: 20655327
[TBL] [Abstract][Full Text] [Related]
19. A nonclassical 5-hydroxytryptamine receptor positively coupled with adenylate cyclase in the central nervous system.
Dumuis A; Bouhelal R; Sebben M; Cory R; Bockaert J
Mol Pharmacol; 1988 Dec; 34(6):880-7. PubMed ID: 2849052
[TBL] [Abstract][Full Text] [Related]
20. 5-HT receptors mediating external carotid vasoconstriction in vagosympathectomized dogs.
Villalón CM; Centurión D; Sánchez-López A; De Vries P; Saxena P
Zhongguo Yao Li Xue Bao; 1999 Dec; 20(12):1057-67. PubMed ID: 11216445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
